6:21 PM
 | 
Jul 27, 2017
 |  BC Extra  |  Company News

Alexion refocusing on complement cascade

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) restructured its pipeline to focus on its core complement inhibitor franchise and its approved rare disease products, dropping early stage rare disease partnerships with Moderna Therapeutics Inc. (Cambridge, Mass.), Blueprint Medicines Corp. (NASDAQ:BPMC) and Arbutus Biopharma Corp. (NASDAQ:ABUS).

Alexion’s shares gained $2.85 to $133.92 on Thursday, when it also announced 2Q17 earnings that beat the Street and raised its guidance for 2017.

The biotech plans to discontinue at least six candidates, including ALXN1630, an mRNA...

Read the full 393 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >